Center for Vision Science, Ruhr University Eye Clinic, Bochum, Germany.
Ophthalmology. 2011 Jul;118(7):1236-41. doi: 10.1016/j.ophtha.2010.12.005. Epub 2011 Mar 24.
To determine whether residual spherical and cylindrical errors could be corrected postoperatively using spatially profiled UV light irradiation in patients with axial hyperopia undergoing cataract surgery and implantation of a light adjustable, silicone intraocular lens (LAL).
We conducted a prospective, nonrandomized clinical trial. The LALs were implanted in eyes with axial lengths <22.20 mm and were treated with a spatial intensity profile delivered by a digital light delivery device to induce a targeted spherical and cylindrical refractive change postoperatively. Once the desired correction was achieved, the LAL was treated again to lock-in the lens power.
We studied 15 eyes of 15 patients with axial hyperopia.
The manifest refraction, uncorrected visual acuity (UCVA), and best spectacle-corrected visual acuity (BCVA) were determined with follow-up time of 12 months to determine the achieved refractive corrections and their stability.
We measured UCVA, BCVA, achieved versus targeted refractive outcome, and refractive stability with a follow-up time of 12 months.
Of 15 eyes, 14 (93%) achieved ± 0.5 diopters (D), and 10 (67%) were within ± 0.25 D of the targeted refractive adjustment up to 12 months postoperative follow-up. Only 1 treated eye showed a change of 0.38 D in manifest spherical equivalent refraction, the remaining 14 eyes showed <0.25 D change between 1 month post lock-in, and at the 3-, 6-, and 12-month postoperative visits.
The light-adjustable lens is a promising technology with the potential to reduce the rate of postoperative refractive surprises up to 2 D of spherical and cylindrical errors after cataract surgery. Postoperative refractive errors were successfully corrected with precision and significant improvement in UCVA and without compromising BCVA using the light-adjustable intraocular lens technology. The data demonstrate the stability of the achieved refractive change after the adjustment and lock-in procedures.
在接受白内障手术和植入可调节、硅胶型人工晶状体（LAL）的轴向远视患者中，通过空间分布的紫外光照射，确定术后能否矫正残余的球镜和柱镜误差。
前瞻性、非随机临床试验。在眼轴长度<22.20mm的情况下植入 LAL，并通过数字光传递装置提供的空间强度分布对其进行处理，以诱导术后靶向球镜和柱镜屈光变化。一旦达到预期的矫正效果，再次对 LAL 进行处理以锁定晶状体的屈光度。
我们研究了 15 例轴向远视患者的 15 只眼。
在 12 个月的随访时间内，通过检测客观折射、未矫正视力（UCVA）和最佳矫正视力（BCVA），确定所达到的折射矫正效果及其稳定性。
我们在 12 个月的随访时间内测量 UCVA、BCVA、实际与目标折射结果的差异以及折射稳定性。
15 只眼中，14 只（93%）眼达到±0.5 屈光度（D），10 只（67%）眼达到±0.25D 的目标屈光调整，直至术后 12 个月随访。只有 1 只治疗眼的显性等效球镜屈光度发生了 0.38D 的变化，其余 14 只眼在锁定后 1 个月、3 个月、6 个月和 12 个月的随访中，屈光度变化<0.25D。
可调节人工晶状体技术具有广阔的应用前景，有望降低白内障手术后 2D 以内的球镜和柱镜误差导致的术后屈光意外发生率。通过使用可调节人工晶状体技术，我们可以精确地矫正术后屈光误差，显著提高 UCVA，同时不影响 BCVA。数据表明，在调整和锁定程序后，所达到的折射变化具有稳定性。
